Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04602221

Organisation Name: Boehringer Ingelheim

Overal Status: Recruiting

Start Date: December 1, 2020

Last Update: June 7, 2021

Lead Sponsor: Boehringer Ingelheim

Brief Summary: The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.

Conditions:
  • Healthy


Total execution time in seconds: 0.23669815063477